The potent, allosteric Akt inhibitor, MK2206, has demonstrated in vitro activity against both thyroid and breast cancer cell lines with PI3KCA mutations [67–71] and, in a breast cancer PTEN mutated xenograft model, MK2206 inhibited tumor growth [68]. This evidence concerns the gene AKT1 and neoplasm.